Apidra solostar and Repaglinide drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Apidra solostar and Repaglinide. Common interactions include pruritus among females and blood creatinine increased among males.

The phase IV clinical study analyzes what interactions people who take Apidra solostar and Repaglinide have. It is created by eHealthMe based on reports of 14 people who take Apidra solostar and Repaglinide from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.



On Jul, 29, 2022

14 people who take Apidra solostar and Repaglinide together, and have interactions are studied.


What is Apidra solostar?

Apidra solostar has active ingredients of insulin glulisine recombinant. It is often used in type 1 diabetes. eHealthMe is studying from 1,692 Apidra solostar users for its effectiveness, alternative drugs and more.

What is Repaglinide?

Repaglinide has active ingredients of repaglinide. It is often used in diabetes. eHealthMe is studying from 6,246 Repaglinide users for its effectiveness, alternative drugs and more.

Number of Apidra solostar and Repaglinide reports submitted per year:

Apidra solostar and Repaglinide drug interactions.

Common Apidra Solostar and Repaglinide drug interactions by gender *:

female:

  1. Pruritus
  2. Rash
  3. Respiratory tract infection
  4. Burning sensation
  5. Erythema

male:

  1. Blood creatinine increased
  2. Cardiac failure
  3. Gastrointestinal stoma complication
  4. Hyperthermia
  5. Blood culture positive
  6. Bacterial sepsis
  7. Hypoglycaemic coma
  8. Bacterial test positive

Common Apidra Solostar and Repaglinide drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Erythema
  2. Pruritus
  3. Rash
  4. Burning sensation

60+:

  1. Blood creatinine increased
  2. Cardiac failure
  3. Gastrointestinal stoma complication
  4. Hyperthermia
  5. Blood culture positive
  6. Bacterial sepsis
  7. Hypoglycaemic coma
  8. Bacterial test positive
  9. Respiratory tract infection

Common conditions people have *:

  1. Osteomyelitis (infection of bone): 11 people, 78.57%
  2. High Blood Pressure: 11 people, 78.57%
  3. Corynebacterium Infection (infection by corynebacterium (diphtheria)): 11 people, 78.57%
  4. Arthritis Infective (purulent invasion of a joint by an infectious agent which produces arthritis): 10 people, 71.43%
  5. Pain: 9 people, 64.29%
  6. Fever: 9 people, 64.29%
  7. Coronary Heart Disease (narrowing or blockage of the coronary arteries): 9 people, 64.29%
  8. Constipation: 9 people, 64.29%
  9. Cardiac Failure: 9 people, 64.29%
  10. Type 2 Diabetes: 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Apidra solostar and Repaglinide?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Apidra solostar and Repaglinide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Apidra solostar interactions:

Browse all interactions between Apidra solostar and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Repaglinide interactions:

Browse all interactions between Repaglinide and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on insulin glulisine recombinant and repaglinide (the active ingredients of Apidra solostar and Repaglinide, respectively), and Apidra solostar and Repaglinide (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: